Plain-English translation of NCT07226544 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called in people with high-risk kidney cancer that hasn't spread beyond the kidney. You would receive this medication intravenously (through an IV) four times over three months, then have surgery to remove the affected kidney. The study wants to see if giving this treatment before surgery helps shrink the cancer and improves how well patients do after the operation.
Currently, patients with aggressive kidney cancer often have surgery first and then receive treatment afterward, but cancer can return. Researchers believe that giving this medication before surgery might help shrink the tumor, make surgery safer and more effective, and reduce the chance that cancer comes back.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic once every three weeks for four visits to receive the intravenous medication, with each infusion taking 1–2 hours. Before treatment starts, you'll have a biopsy, heart ultrasound, and CT scan. Between 4–10 weeks after finishing the medication, you'll have surgery to remove your kidney. After surgery, you'll return for follow-up visits every 12 weeks for two years to check on your recovery and health. Blood tests and imaging scans will be done throughout to monitor your response and safety.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States